QURIENT CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3,710 KRW | +4.95% |
|
-1.07% | -20.56% |
| Sales 2022 | 8.47K 11.72M 707K | Sales 2023 | 9.03K 12.5M 754K | Capitalization | 90.36B 1,25,024B 7,539B |
|---|---|---|---|---|---|
| Net income 2022 | -25.46B -35,224B -2,124B | Net income 2023 | -21.12B -29,219B -1,762B | EV / Sales 2022 | 1,03,69,450 x |
| Net cash position 2022 | 32.29B 44,680B 2,694B | Net cash position 2023 | 42.49B 58,788B 3,545B | EV / Sales 2023 | 53,00,023 x |
| P/E ratio 2022 |
-5.02
x | P/E ratio 2023 |
-3.91
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 92.92% |
More Fundamentals
* Assessed data
More news
| 1 day | +4.95% | ||
| 1 week | -1.07% | ||
| Current month | -12.40% | ||
| 1 month | -12.29% | ||
| 3 months | -16.82% | ||
| 6 months | -40.64% | ||
| Current year | -20.56% |
1 week
3 450.00
4 000.00
1 month
3 450.004 710.00
Current year
3 450.005 030.00
1 year
2 361.548 269.23
3 years
2 361.5415 076.92
5 years
2 361.5432 653.85
10 years
2 361.5446 384.62
| Managers | Title | Age | Since |
|---|---|---|---|
Ki-Yean Nam
CEO | Chief Executive Officer | 53 | 02/08/02 |
Peter Yu
DFI | Director of Finance/CFO | 51 | 01/22/01 |
Gi-Won Choi
COO | Chief Operating Officer | 52 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ki-Yean Nam
CEO | Chief Executive Officer | 53 | 02/08/02 |
Jae-Seung Kim
BRD | Director/Board Member | 56 | - |
Gi-Won Choi
COO | Chief Operating Officer | 52 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 19/24/19 | 3,710 | +4.95% | 124,740 |
| 18/24/18 | 3,535 | -0.98% | 51,907 |
| 17/24/17 | 3,570 | -2.99% | 117,735 |
| 14/24/14 | 3,680 | -2.00% | 242,727 |
| 13/24/13 | 3,755 | +0.13% | 77,755 |
End-of-day quote Korea S.E., June 19, 2024
More quotes
Qurient Co., Ltd. is a Korea-based company mainly engaged in the research and development of pharmaceuticals. The Company includes two programs: development phase programs and research phase programs. The development phase programs consist of Q203 which is drug-resistant tuberculosis treatment drug, Q301 which is atopic dermatitis treatment dug and Q701 which is used for treatment of drug resistant cancer and promotion anti-cancer immunotherapy. The research phase programs consist of 5 lipoxygenase (5LO) inhibit asthma medicines and cyclin dependent kinase 7 (CDK7) inhibit cancer drug.
Sector
Pharmaceuticals
Calendar
13/08/2024
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -20.56% | 84.46M | |
| +30.23% | 78.37B | |
| +3.26% | 25.35B | |
| +15.18% | 8.8B | |
| +8.80% | 8.37B | |
| -27.86% | 7.34B | |
| +1.17% | 4.14B | |
| -9.21% | 3.78B | |
| -5.60% | 3.5B | |
| +11.43% | 3.33B |
- Stock Market
- Equities
- A115180 Stock
